Daniel Christ

Biography

 Daniel is the Founder and Chief Scientific Officer of Solvanix. He presently heads the Antibody Therapeutics Laboratory at the Garvan Institute of Medical Research in Sydney and holds a conjoint appointment as Associate Professor of Medicine at UNSW Australia. His research at the Garvan focuses on the engineering of antibodies and cytokines for medical applications. He holds a first class degree from the Swiss Federal Institute of Technology (ETH) and a PhD from Cambridge University, where he worked with Sir Gregory Winter at the MRC Laboratory of Molecular Biology (LMB). Winter had shown that in vitro evolution technology (such as phage display) could be used for the generation of therapeutic antibodies, initiating a multi-billion dollar biotechnology industry. At Cambridge, Christ and Winter further developed monoclonal antibody technology, particularly in the field of domain antibodies (commercialised through Domantis Ltd – sold to GSK for £230 million in 2006). Dr Christ’s work has attracted in excess of $5 million of compeptitive research funding and numerous awards, including a fellowship of Trinity College (Cambridge University) and an NHMRC excellence award.

Research Interest

  Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management